<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01103245</url>
  </required_header>
  <id_info>
    <org_study_id>091072</org_study_id>
    <secondary_id>09CRP2261428</secondary_id>
    <nct_id>NCT01103245</nct_id>
  </id_info>
  <brief_title>Aldosterone and the Metabolic Syndrome</brief_title>
  <official_title>Aldosterone and the Metabolic Syndrome: Renin Inhibition Versus Mineralocorticoid Receptor (MR) Antagonism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of mineralocorticoid receptor (MR)
      antagonism and renin inhibition on glucose metabolism in humans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the effects of mineralocorticoid receptor (MR)
      antagonism and renin inhibition on fasting blood glucose and glucose-stimulated insulin
      secretion in humans.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">January 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma glucose and insulin concentrations</measure>
    <time_frame>3 hours</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Metabolic Diseases</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Endocrine System Diseases</condition>
  <condition>Glucose Metabolism Disorders</condition>
  <arm_group>
    <arm_group_label>Renin-Angiotensin Aldosterone Activation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Renin-Angiotensin-Aldosterone System (RAAS) Activation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aliskiren, Spironolactone, or Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Determination of effects of MR antagonism or renin inhibition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Increased Dose, Combination, or Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Determination of effects of MR antagonism and/or renin inhibition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Renin-Angiotensin-Aldosterone System (RAAS) Activation</intervention_name>
    <description>Subjects will be receive a dose of Hydrochlorothiazide (HCTZ) for 12 weeks and be given a calculated diet during the last 5 days of this period. Serum potassium levels, urine samples, and blood levels of insulin secretion will be measured.</description>
    <arm_group_label>Renin-Angiotensin Aldosterone Activation</arm_group_label>
    <other_name>HCTZ, Professional Compounding Centers of America (PCCA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of Aliskiren, Spironolactone, or Placebo</intervention_name>
    <description>Subjects will be receive a dose of Aliskiren, Spironolactone, or placebo for 4 weeks and be given a calculated diet during the last 5 days of this period. Serum potassium levels, urine samples, and blood levels of insulin secretion will be measured.</description>
    <arm_group_label>Aliskiren, Spironolactone, or Placebo</arm_group_label>
    <other_name>Aliskiren (ALI)- brand name: Tekturna - company: Novartis AG</other_name>
    <other_name>Spironolactone (SPL)- generic brand from PCCA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Increased Dose, Combination, or Placebo</intervention_name>
    <description>Subjects will be receive either an increased dose of the present medication (Aliskiren or Spironolactone) or a combination of the two or a placebo for 4 weeks and be given a calculated diet during the last 5 days of this period. Serum potassium levels, urine samples, and blood levels of insulin secretion will be measured.</description>
    <arm_group_label>Increased Dose, Combination, or Placebo</arm_group_label>
    <other_name>Aliskiren (ALI)- brand name: Tekturna - company: Novartis AG</other_name>
    <other_name>Spironolactone (SPL)- generic brand from PCCA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects meeting all of the following conditions will be included in the study:

               1. Ambulatory subjects, 18 to 70 years of age, inclusive

               2. For female subjects, the following conditions must be met:

                    1. postmenopausal status for at least 1 year, or

                    2. status-post surgical sterilization, or

                    3. if of childbearing potential, utilization of adequate birth control and
                       willingness to undergo urine beta-hcg testing prior to drug treatment and on
                       every study day.

               3. A seated or supine systolic blood pressure greater than 130/85 on three separate
                  measurements at least 15 minutes apart

               4. Metabolic Syndrome as defined by the presence of &gt; 3 of the following:

                    1. Hypertension as characterized by having Systolic Blood Pressure &gt; 140 mm Hg
                       and Diastolic Blood Pressure &gt; 90 mm Hg.

                    2. Impaired Glucose Tolerance (Fasting Plasma Glucose &gt; 100 mg/dL)

                    3. Increased triglyceride level &gt; 150mg/dL

                    4. Decreased levels of High-Density Lipoprotein (HDL) cholesterol

                         1. For males, less than 30 mg/dL

                         2. For females, less than 40 mg/dL

                    5. Waist circumference

                         1. For males, greater than 40 inches.

                         2. For females, greater than 35 inches.

        Exclusion Criteria:

          -  Subjects presenting with any of the following will not be included in the study:

               1. Diabetes type 1 or type 2, a fasting glucose of greater than 110 mg/dL or the use
                  of anti-diabetic medication

               2. Use of hormone replacement therapy

               3. Statin therapy

               4. Pregnancy

               5. Breast-feeding

               6. Cardiovascular disease such as prior myocardial infarction, presence of angina
                  pectoris, significant arrhythmia, congestive heart failure [Left Ventricular (LV)
                  hypertrophy acceptable], deep vein thrombosis, pulmonary embolism, second or
                  third degree heart block, mitral valve stenosis, aortic stenosis or hypertrophic
                  cardiomyopathy

               7. Treatment with anticoagulants

               8. History of serious neurologic disease such as cerebral hemorrhage, stroke,
                  seizure, or transient ischemic attack

               9. History or presence of immunological or hematological disorders

              10. Diagnosis of asthma requiring use of inhaled beta agonist &gt;1 time per week

              11. Clinically significant gastrointestinal impairment that could interfere with drug
                  absorption

              12. Impaired hepatic function [aspartate amino transaminase (AST) and/or alanine
                  amino transaminase (ALT) &gt;1.5 x upper limit of normal range]

              13. Impaired renal function [estimated glomerular filtration rate (eGFR) of
                  &lt;60ml/min] as determined by the four-variable Modification of Diet in Renal
                  Disease (MDRD) equation, where serum creatinine (Scr) is expressed in mg/dl and
                  age in years:

                  eGFR (ml/min/1.73m2)=175 • Scr-1.154 • age-0.203 • (1.212 if black) • (0.742 if
                  female)

              14. Hematocrit &lt;35%

              15. Any underlying or acute disease requiring regular medication which could possibly
                  pose a threat to the subject or make implementation of the protocol or
                  interpretation of the study results difficult, such as arthritis treated with
                  non-steroidal antiinflammatory drugs

              16. Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive
                  days in 1 month)

              17. Treatment with lithium salts

              18. History of alcohol or drug abuse

              19. Treatment with any investigational drug in the 1 month preceding the study

              20. Mental conditions rendering the subject unable to understand the nature, scope
                  and possible consequences of the study

              21. Inability to comply with the protocol, e.g., uncooperative attitude, inability to
                  return for follow-up visits, and unlikelihood of completing the study

              22. Screening plasma potassium &lt;3.2 mmol/L or use of chronic potassium supplements
                  for the treatment of hypokalemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James M Luther, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Loretta Byrne, RN</last_name>
    <phone>615-322-2105</phone>
    <email>loretta.byrne@vanderbilt.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>James Luther, MD</last_name>
    <phone>615-343-8701</phone>
    <email>james.luther@vanderbilt.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loretta Byrne, RN</last_name>
      <phone>615-322-2105</phone>
      <email>loretta.byrne@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>James M Luther, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maneesh C. Kanal, BA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2010</study_first_submitted>
  <study_first_submitted_qc>April 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2010</study_first_posted>
  <last_update_submitted>August 4, 2011</last_update_submitted>
  <last_update_submitted_qc>August 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>James M. Luther, MD, MSCI</name_title>
    <organization>Vanderbilt University Medical Center</organization>
  </responsible_party>
  <keyword>Glucose</keyword>
  <keyword>Insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Lactitol</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 19, 2017</submitted>
    <returned>June 30, 2017</returned>
    <submitted>March 26, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

